Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat.
Heart disease is the leading cause of morbidity and mortality. Cardiac gene transfer may serve as a novel therapeutic approach. This investigation was undertaken to compare cardiac tropisms of adeno-associated virus (AAV) serotypes 1, 6, 7, 8, and 9. Neonatal mice were injected with 2.5 x 10(11) genome copies (GC) of AAV serotype 1, 6, 7, 8, or 9 expressing LacZ under the control of the constitutive chicken beta-actin promoter with cytomegalovirus enhancer promoter via intrapericardial injection and monitored for up to 1 year. Adult rats were injected with 5 x 10(11) GC of the AAV vectors via direct cardiac injection and monitored for 1 month. Cardiac distribution of LacZ expression was assessed by X-Gal histochemistry, and beta-galactosidase activity was quantified in a chemiluminescence assay. Cardiac functional data and biodistribution data were also collected in the rat. AAV9 provided global cardiac gene transfer stable for up to 1 year that was superior to other serotypes. LacZ expression was relatively cardiac specific, and cardiac function was unaffected by gene transfer. AAV9 provides high-level, stable expression in the mouse and rat heart and may provide a simple alternative to the creation of cardiac-specific transgenic mice. AAV9 should be used in rodent cardiac studies and may be the vector of choice for clinical trials of cardiac gene transfer.
Bish
Lawrence T
LT
Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. bish@mail.med.upenn.edu
Morine
Kevin
K
Sleeper
Meg M
MM
Sanmiguel
Julio
J
Wu
Di
D
Gao
Guangping
G
Wilson
James M
JM
Sweeney
H Lee
HL
D000818:Animals; D000831:Animals, Newborn; D000229:Dependovirus / Q000145:classification / Q000235:genetics*; D018014:Gene Transfer Techniques; D005822:Genetic Vectors; D051379:Mice; D009206:Myocardium / Q000378:metabolism*; D051381:Rats; D013045:Species Specificity; D001616:beta-Galactosidase / Q000235:genetics
D001616:beta-Galactosidase
J Virol. 2005 Jun;79(11):6801-7
15890919
Mol Ther. 2004 Sep;10(3):604-8
15336660
Gene Ther. 2007 Nov;14(22):1605-9
17898796
Circ Res. 2006 Aug 18;99(4):e3-9
16873720
Gene Ther. 2003 Dec;10(26):2112-8
14625565
J Gene Med. 2008 Feb;10(2):132-42
18064719
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11854-9
12192090
J Mol Cell Cardiol. 1999 Apr;31(4):721-32
10329200
Cardiovasc Res. 2006 Apr 1;70(1):6-8
16524565
Mol Ther. 2006 Jul;14(1):45-53
16713360
J Virol. 2004 Jun;78(12):6381-8
15163731
Gene Ther. 2007 Jul;14(13):989-97
17251988
Mol Ther. 2004 Dec;10(6):981-9
15564130
Circulation. 2007 May 15;115(19):2506-15
17470693
Cardiovasc Res. 2006 Apr 1;70(1):70-8
16448634
J Card Fail. 2008 Jun;14(5):355-67
18514926
Cardiovasc Res. 2007 Feb 1;73(3):453-62
17097076
Mol Ther. 2008 Jun;16(6):1073-80
18414476
Int J Cardiol. 2005 Apr 28;100(3):421-6
15837086
Gene Ther. 2001 Aug;8(16):1248-54
11509958
J Virol. 2001 Jul;75(13):6199-203
11390622
Circulation. 2003 Sep 30;108(13):1626-32
12952841
J Mol Cell Cardiol. 2007 Apr;42(4):852-61
17300800
Blood. 2005 May 1;105(9):3458-64
15479726
Genet Vaccines Ther. 2007 Dec 10;5:13
18070352
Basic Res Cardiol. 2001 May-Jun;96(3):227-36
11403416
J Heart Lung Transplant. 2008 May;27(5):554-60
18442723
Transpl Int. 2007 Jun;20(6):550-7
17403107
Gene Ther. 2007 Sep;14(18):1319-29
17611587
J Thromb Haemost. 2007 Jan;5(1):16-24
17002653
Mol Ther. 2005 Jun;11(6):980-5
15922969